+8615710194249

News Center

Development history of mRNA CDMO

2024-01-29

The development of mRNA CDMO can be traced back to recent years. With the outbreak of the new crown epidemic, mRNA technology has attracted global attention for its ability to rapidly develop and produce vaccines. In this context, mRNA CDMOs (Contract Development and Manufacturing Organizations) are emerging.

In 2019, mRNA technology companies began to rise, including BioNTech and Moderna. As the demand for vaccine research and development increased, these companies began to seek partners to expand production capacity and promote the development of mRNA CDMO.

In 2020, the global demand for mRNA vaccines will increase sharply due to the outbreak of the new crown epidemic. In order to meet the needs of the global market, mRNA CDMO is actively expanding its production capacity, investing more in research and development, and cooperating with pharmaceutical companies.

With the successful launch of the mRNA vaccine in 2021, mRNA CDMO has seen explosive growth. More and more pharmaceutical companies and institutions are looking to collaborate with mRNA CDMOs to develop and manufacture a variety of mRNA therapies, including not only vaccines, but also treatments for cancer, cardiovascular disease, and more.

In the future, with the continuous development of mRNA technology and the expansion of applications, mRNA CDMO will continue to grow. It is expected that in the coming years, mRNA CDMOs will become an important part of the pharmaceutical industry, providing more innovative mRNA therapies to the world.